Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 12, 2025 along with the Annual Report
SPARC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SPARC has submitted its Annual Report for FY 2024-25 along with the Notice for its 20th AGM, scheduled for August 12, 2025 at 4:00 PM via video conferencing, with remote e-voting open from August 8 to August 11, 2025. For FY25, the company reported a standalone loss after tax of ₹34,522 lakhs, narrower than the ₹38,810 lakh loss in FY24, while revenue from operations declined to ₹7,177 lakhs from ₹7,555 lakhs. The board has not recommended any dividend due to continued losses, and accumulated negative retained earnings stood at ₹2,32,521 lakhs. Two new independent directors—Ms. Rekha Warriar and Mr. Venkateswarlu Jasti—have been appointed w.e.f. May 19, 2025, while Ms. Bhavna Doshi and Dr. Ferzaan Engineer will retire at the upcoming AGM. The bank loan credit rating remains at Acuite AA- (Stable), and the company continues to rely heavily on related-party transactions with promoter group entities, notably Shanghvi Finance (₹10,271 lakhs) and Sun Pharmaceutical Industries Ltd (₹8,218 lakhs).
This is a routine regulatory filing with no fresh business triggers; shareholders should review the AGM agenda for director appointments and any voting items. The narrowing but still significant losses and absence of dividend reinforce that SPARC remains in an R&D-heavy phase with limited near-term earnings visibility.